Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

120.73 -0.00 (-0.00%)
Streaming Delayed Price Updated: 12:04 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
1 Healthcare Stock to Consider Right Now and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles
September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains. 
Via Benzinga
Topics Stocks
Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report
The company beat second-quarter expectations, with the exception of one key metric. 
Via Investor's Business Daily
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
CVS Health Reportedly Keeps Gilead’s New HIV Preventative Shot Off Its Plans, Faces $290M Medicare Fraud Ruling
Via Stocktwits
Topics Fraud
Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
The drug is soon to launch in Europe with a new name and a big potential market. 
Via Investor's Business Daily
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences
While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an opportunity. 
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
The tariffs will impact products imported from Europe, the Trump administration said late Thursday. 
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
Market Monitor News August 22 BMO - Coty Crumbles, Powell Looms: Wall Street Cautious Amid Mixed Signals
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data... 
Via Chartmill
Topics Economy
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access. 
Via Benzinga
Why Gilead Sciences (GILD) Shares Are Sliding Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to... 
Via StockStory
Topics Earnings
These S&P500 stocks are gapping in today's session
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug. 
Via Investor's Business Daily
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Walgreens Grows Specialty Pharmacy Network To Meet Rising Demand For Complex Therapies
Walgreens boosts specialty drug network to 265 therapies, reinforcing its independent market position. 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Presents a Compelling Case for Value Investors
Gilead Sciences (GILD) appears undervalued with strong profitability, a solid dividend, and moderate growth, offering a compelling case for value investors. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
NAFA Publishes New Fleet Safety Guidebook Aimed at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Xilio Revenue Jumps 246 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention.... 
Via StockStory
Topics Earnings
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
Is Gilead Sciences Gaining or Losing Market Support?
 
Via Benzinga
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s... 
Via StockStory
Kymera Revenue Drops 55 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Market Monitor News August 11 BMO - Nasdaq Breaks Records, But The Trade Desk Hits a Wall
Markets ended the week in high spirits, but not everyone joined the party. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.